In this context, we reasoned that palbociclib, a CDK4/6 inhibitor that is capable of regulating the cell cycle machinery [27], could modulate ERα expression in endometrial cancer cells by affecting the NPM/B23 phosphorylation status. Here, CDK4 is linked to endometrial cancer.